Category: Research

Veridian Deal Tracker for the Week Ended November 10, 2017

SHARE THIS POST November 10, 2017 – Year to date, more than $2.3 billion has been raised into cannabis and cannabis-related businesses, up 178% over the $848 million raised for the same period last year. Average deal size year-to-date is at $7.1 million, up 136%, while the total number of deals done, equity and debt year-to-date is 259, up 62%. TroyFlowers Author description...

Read More

Federal Government Grants $3.2 Million to Medical Cannabis Research for HIV Patients

Getty Despite the fact that the U.S. federal government has steadfastly refused to change the Schedule I classification of the cannabis plant, they are reportedly handing out millions to researchers in order to explore its effectiveness in treating symptoms experienced by HIV patients. Will this ridiculously overt display of federal government hypocrisy regarding cannabis medicine end up being a net positive? The National Institute on Drug Abuse (NIDA) recently awarded a team of scientific researchers at the University of Florida a $3.2 million grant in order to determine what just about every medical cannabis supporter already pretty much knows...

Read More

World Health Organization Explores International Rescheduling of CBD at Expert Committee Meeting

by Todd | Oct 26, 2017 | General, Medical Cannabis, Pharma & Biotech, Research | 0 comments October 26, 2017 Raul Elizalde to speak before WHO Expert Committee on Drug Dependence review of the psychoactivity of CBD. On November 6th, the World Health Organization’s (WHO) Thirty-Ninth meeting of the Expert Committee on Drug Dependence will begin a 5-day agenda set to determine the potential for harm or dependance of 16 different substances, including cannabidiol (CBD). Medical Marijuana, Inc. subsidiary HempMeds® will have a representative speaking before the committee on the first day regarding CBD. While WHO recognizes the medical use of certain substances is indispensable in the treatment of many conditions and that they should be available to patients for such purposes, the committee is also tasked with determining which substances should be regulated or banned internationally as scheduled drugs. WHO has a part in two of the United Nation’s central drug control conventions – the 1961 Single Convention on Narcotic Drugs and 1971 Convention on Psychotropic substances. WHO is responsible for conducting the medical, scientific, and public health evaluation of potentially harmful substances to determine the UN’s role in regulating them. This is done through the thirteen member Expert Committee on Drug Dependence (ECDD). The committee is made up of an international panel of experts in the field of drug addiction and abuse. The ECDD evaluates the dependence-producing...

Read More

New Study Finds Legalization Hasn’t Increased Cannabis Use

Getty A new study published in the journal Addiction has found that legalization is not a contributing factor to increased cannabis use among adults in the United States. The study was conducted by researchers at the Public Health Institute’s Alcohol Research Group, and they used data provided by periodic national alcohol surveys. That data was compared to results on cannabis use from those surveys, which was looked at alongside changes in state marijuana laws. “Results …did not show significant increases in use related to medicinal marijuana legislation,” William Kerr, author of the study, said in a statement. “It appears...

Read More

U.S. Senate Wants More Reliable Information on Cannabis

Getty The U.S. Senate Appropriations Committee is calling for the National Institute on Drug Abuse (NIDA) and the Drug Enforcement Administration (DEA) to create a “National Testing Program for Schedule I Marijuana-Derived Products.” Essentially, they are asking for these federal agencies to study cannabis samples in an effort to “provide robust reliable data that can inform policy.” Up until 2014, NIDA funded a program for testing cannabis samples seized by law enforcement – but there has never been testing at the federal level on samples sold from commercial (recreational) cannabis dispensaries. The program the Senate is suggesting would do...

Read More